老年房颤患者口服抗凝药的有效性与安全性
结果显示标准剂量与减量NOACs的卒中/系统性栓塞风险与华法林相似,阿哌沙班大出血风险低于华法林,NOACs在老年患者中似乎是安全选择。
要点
- ≥75岁房颤患者中,标准剂量NOACs的卒中/系统性栓塞风险与华法林相似。
- 阿哌沙班大出血风险低于华法林(SHR 0.74,95%CI 0.60-0.91)。
- 减量NOACs与华法林相比,卒中/栓塞和出血风险结果相似。
核心结论
- 在≥75岁房颤口服抗凝初始患者中,标准剂量和减量NOACs的卒中/系统性栓塞风险与华法林相似,出血风险更低或相似。
研究设计与样本
- 使用多变量竞争风险回归计算NOACs相比华法林的亚风险比(SHR)。
主要发现
- 标准剂量NOACs相比华法林卒中/系统性栓塞的SHR:达比加群0.80(95%CI 0.57-1.13),利伐沙班1.07(95%CI 0.89-1.30),阿哌沙班0.95(95%CI 0.78-1.15)。
- 标准剂量NOACs相比华法林大出血的SHR:达比加群0.75(95%CI 0.52-1.08),利伐沙班0.96(95%CI 0.78-1.16),阿哌沙班0.74(95%CI 0.60-0.91)。
- 减量NOACs与华法林比较结果相似,敏感性分析与主要结果一致。
临床怎么用
- 对于≥75岁房颤患者,NOACs可作为与华法林疗效相当且出血风险不增加的安全选择。
- 阿哌沙班在老年患者中显示出较华法林更低的大出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the risk of stroke/systemic embolism (SE) and major bleeding associated with the use of oral anticoagulants in elderly patients with atrial fibrillation (AF) in a real-world population. METHODS: We identified all anticoagulant-naive initiators of warfarin, dabigatran, rivaroxaban and apixaban for the indication AF in Norway between January 2013 and December 2017. Multivariate competing risk regression was used to calculate subhazard ratios (SHRs) describing associations between non-vitamin K antagonist oral anticoagulants (NOACs) compared with warfarin for risk of stroke/SE and major bleeding. RESULTS: Among 30 401 patients ≥75 years identified (median age 82 years, 53% women, mean CHA2DS2-VaSc score 4.5), 3857 initiated dabigatran, 6108 rivaroxaban, 13 786 apixaban and 6650 warfarin. Reduced dose was initiated in 11 559 (49%) of the NOAC-treated patients. For stroke, the SHRs for standard dose NOAC against warfarin were 0.80 (95% CI 0.57 to 1.13) for dabigatran; 1.07 (95% CI 0.89 to 1.30) for rivaroxaban and 0.95 (95% CI 0.78 to 1.15) for apixaban. For major bleeding, the SHRs against warfarin were 0.75 (95% CI 0.52 to 1.08) for dabigatran; 0.96 (95% CI 0.78 to 1.16) for rivaroxaban and 0.74 (95% CI 0.60 to 0.91) for apixaban. Comparing reduced doses of NOACs with warfarin yielded similar results. Sensitivity analyses were in accordance with the main results. CONCLUSION: In this nationwide cohort study of patients ≥75 years initiating oral anticoagulation for AF, standard and reduced dose NOACs were associated with similar risks of stroke/SE as warfarin and lower or similar risks of bleeding. The NOACs seem to be a safe option also in elderly patients.
引用
- Rutherford OW, Jonasson C, Ghanima W, et al. Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation. Heart. 2021. PMID: 33975877. doi:10.1136/heartjnl-2020-318753
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。